Hangzhou Xinfu Science & Technology Co., Ltd.

The website listed for Hangzhou Xinfu Science and Technology Co., Ltd. now serves Yifan Pharmaceutical Co., Ltd., a Hangzhou-based company listed on the Shenzhen Stock Exchange under code 002019. Its filings and site are registered in Zhejiang.

Yifan works in four areas: biologics, small molecules, synthetic biology products and characteristic traditional Chinese medicines. The synthetic biology side is the part relevant to food and nutrition ingredients, and the company states that it has an industrial scale-up system for synthetic biology products and works with synthetic biology companies in China and abroad. It also describes dedicated research and technology platforms for pharmaceutical raw materials and excipients, covering vitamins, antivirals, cytotoxics and contrast agents, using continuous flow reaction, solid phase peptide synthesis and high-potency handling.

Research is run from five centres, in San Francisco, Shanghai, Beijing, Hangzhou and Hefei, with close to 50 products in development. The company has more than ten manufacturing bases in China and overseas built to NMPA, FDA and EMA cGMP requirements, with over a hundred production lines for various dosage forms. It holds more than 300 product approvals, including over 40 registered outside China, and has commercial operations in more than 40 countries and regions. Its subsidiary Evive Biotech developed Ryzneuta, a long-acting G-CSF approved by the NMPA in 2023 and launched in Germany in 2024.